
- CB1 Allosteric Enhancers
- CB1 Allosteric Inhibitors
- GPR55 Antagonists
- A Novel Target for Diastolic Heart Failure
- Novel Fungal Diagnostics and Therapeutics
- CB1 Receptor PET Ligands
- Rheumatoid Arthritis
- Antifungal Agents: chitin synthase inhibitors
- A Novel Treatment for Hypertension
- PET Tracers for Alzheimer's Disease
- Insulin Gene Therapy
- HIV Entry Inhibitors
- A Novel Target for Prostate Cancer
- A Novel Anthelmintic Target
- Neuroprotective Agents
- Hypothalamic Receptors for Metabolic Health
- SBF: Delivery of drugs across the BBB using shark VNAR biotools
- 18F-FDR as a New Powerful Radiolabelling Agent for PET
- PET Tracers for Hypoxia
- Angiogenesis Tracers
- Development of PET Tracers for Membrane Transporters
- A Novel Retinoid Pathway
PET Tracers for Hypoxia
Tissue hypoxia, which results from an inadequate supply of oxygen, is found in a variety of solid tumours and is due to functional and structural abnormalities of the tumour vasculature. There is consistent experimental and clinical evidence that tumour hypoxia has an important role in tumour propagation, resistance to therapy and progression. As a result, assays for the detection of hypoxia in patients have been developed to predict outcome and identify patients (1) with a worse prognosis, (2) that would benefit from appropriate treatments. Positron Emission Tomography (PET) is emerging as a powerful imaging technique for identifying and measuring hypoxia through molecular markers. The development of novel PET radiotracers for hypoxia represents a research priority at the University of Aberdeen.
Project Team: Professor Matteo Zanda, Dr Elaina Collie-Duguid, Professor Fiona Gilbert, Professor Andy Welch, Dr Lutz Schweiger and Dr Tim Smith
University of Aberdeen
King's College
Aberdeen
AB24 3FX
